Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
Status:
Recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
Coronary angiography is performed to evaluate for obstructive coronary artery disease. This
is commonly performed via the transfemoral or transradial approach with the latter increasing
in frequency. One of the most common complications of transradial access is radial artery
occlusion occurring in ~5% of patients which prohibits the use of the radial artery in the
future. There is evidence to support the use of intraprocedural anticoagulation to mitigate
the risk of radial artery occlusion however the role of post-procedural anticoagulation has
not been previously evaluated. Rivaroxaban is a direct oral anticoagulant (DOAC) with a
safety profile superior to that of vitamin K antagonists. Given the safety profile, ease of
use, and feasibility of DOAC therapy, our study will endeavor to evaluate the use of
rivaroxaban 15mg orally once daily for 7 days after transradial access and the impact this
has on the rate of radial artery occlusion.